Global organ transplant immunosuppressant market 2017-2021
About Organ Transplant Immunosuppressant
An organ transplantation is a surgical procedure that involves replacing diseased organs such as a heart, liver, kidney, or lung with healthy organs. The donor organ can come from a deceased donor (who has recently passed away) such as in heart transplants, or kidney, liver, and rarely lung transplants from living donors. As per the Centers for Disease Control and Prevention (CDC) report, the most commonly transplanted organs in the US are the kidney, liver, heart, lungs, pancreas, and intestine. On any given day, there are about 75,000 people on active waiting list for organ transplantation. However, the organ donors are very few, leading to the high unmet need for organ availability. There are only 8,000 deceased organ donors annually, with each providing on average 3.5 organs. Living donors provide on average only around 6,000 organs per year.
Technavio’s analysts forecast the global organ transplant immunosuppressant market to grow at a CAGR of 3.81% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global organ transplant immunosuppressant market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Organ Transplant Immunosuppressant Market 2017-2021
Technavio recognizes the following companies as the key players in the global organ transplant immunosuppressant market: Novartis, Astellas Pharma, Pfizer, and Sanofi,
Other Prominent Vendors in the market are: AbbVie, Bristol-Myers Squibb, and F. Hoffmann-La Roche.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is growing trend of medical tourism. Medical tourism is the act of traveling abroad to receive medical, dental, and cosmetic care. Medical tourism for getting an organ transplant is also called as transplant tourism, and the significantly lower cost for availing the best practice care is generally the primary motivation. In addition, the insufficient organ supply is another reason for the emergence of medical/transplant tourism. However, to bridge the gap between demand and supply, the introduction of the artificial organ has served the purpose. However, the high cost associated with artificial organ transplant, especially in the US has further compelled the individuals to visit the less developed countries to get an organ transplant at competitive prices.”
According to the report, one of the major drivers for this market is increased incidence of organ failure. Globally, there is a high demand for tissues and organs such as bone marrow, heart, liver, kidney, and lungs. The increased alcohol consumption, unhealthy lifestyles and food habits, and drug intake are the leading causes of organ failure. In addition, the rise in aging population results in increased demand for organs for transplantation.
Further, the report states that one of the major factors hindering the growth of this market is Insufficient organ supply. The global organ transplant immunosuppressant market is witnessing a high demand for donor organ due to increasing incidences of organ failure. Despite advances in the medicine and technology, and increased awareness of organ donation and transplantation, the increasing gap between supply and demand continues to pose a major challenge for the market growth.
Novartis, Astellas Pharma, Pfizer, Sanofi,AbbVie, Bristol-Myers Squibb, and F. Hoffmann-La Roche.